[MO31] Mini-Oral Session 31　臨床試験推進プログラム1（Trial in Progress）

[MO31-1] A Phase 2 Study of Datopotamab Deruxtecan in Advanced NSCLC With Actionable Genomic Alterations (TROPION-Lung05)

^○葉 清隆¹, Johnson Melissa², Spira Alexander³, Heist Rebecca⁴, Lisberg Aaron⁵, Greenberg Jonathan⁶, Phillips Penny⁶, Lan Lan⁶, Gu Wen⁶, Zhang Yong⁶, Sands Jacob⁷ (1.国立がん研究センター東病院, 2.Sarah Cannon Research Institute, Tennessee Oncology, PLLC/OneOncology, Nashville,TN/United States of America, 3.Virginia Cancer Specialists and US Oncology Research, Fairfax, VA/United States of America, 4.Massachusetts General Hospital, Boston, MA/United States of America, 5.University of California Los Angeles, Los Angeles, CA/United States of America, 6.Daiichi Sankyo, Inc., Basking Ridge, NJ/United States of America, 7.Dana-Farber Cancer Institute, Boston, MA/United States of America)